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Abstract
Background: The immune contribution to cancer progression is complex and difficult to characterize. For example
in tumors, immune gene expression is detected from the combination of normal, tumor and immune cells in the
tumor microenvironment. Profiling the immune component of tumors may facilitate the characterization of the
poorly understood roles immunity plays in cancer progression. However, the current approaches to analyze the
immune component of a tumor rely on incomplete identification of immune factors.
Methods: To facilitate a more comprehensive approach, we created a ranked immunological relevance score for all
human genes, developed using a novel strategy that combines text mining and information theory. We used this
score to assign an immunological grade to gene expression profiles, and thereby quantify the immunological
component of tumors. This immunological relevance score was benchmarked against existing manually curated
immune resources as well as high-throughput studies. To further characterize immunological relevance for genes,
the relevance score was charted against both the human interactome and cancer information, forming an
expanded interactome landscape of tumor immunity. We applied this approach to expression profiles in
melanomas, thus identifying and grading their immunological components, followed by identification of their
associated protein interactions.
Results: The power of this strategy was demonstrated by the observation of early activation of the adaptive
immune response and the diversity of the immune component during melanoma progression. Furthermore, the
genome-wide immunological relevance score classified melanoma patient groups, whose immunological grade
correlated with clinical features, such as immune phenotypes and survival.
Conclusions: The assignment of a ranked immunological relevance score to all human genes extends the content
of existing immune gene resources and enriches our understanding of immune involvement in complex biological
networks. The application of this approach to tumor immunity represents an automated systems strategy that
quantifies the immunological component in complex disease. In so doing, it stratifies patients according to their
immune profiles, which may lead to effective computational prognostic and clinical guides.
Background
Although a link between the immunity and cancer was
observed almost 150 years ago [1], the exact nature of
the relationship has been developed and debated
through several stages of complexity. In recent years, it
has been established that the immune system plays cru-
cial roles in tumor development [2], and indeed on
patient survival for various cancers [3-7]. Due to a lack
of comprehensive analytical approaches, molecular char-
acterization of the roles of the tumor immune compo-
nent has been somewhat difficult to elucidate on a
genome-wide scale.
Current strategies to identify the immune component
of tumors tend to employ incomplete manual efforts
that do not grade the immune genes. Indeed, even the
very definition of an immune gene is unclear, as several
interconnected subsystems comprise the totality of
immunity. In addition, an analysis of the molecular
interactions linked to tumor immunity is usually limited
to a pathway-centric paradigm, which is often hindered
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entangled in signaling crosstalk [8]. These challenges are
further complicated during cancer progression by the
migration of immune cells into unique microenviron-
ments, and by the altered expression of immune genes
intrinsic to the tumor. Consequently, as in a tumor gene
expression profile, it is not trivial to grade the immune
component or identify its related molecular networks.
Multidisciplinary and integrated strategies that handle
these and other complex challenges of tumor immunity
are increasingly sought after [9-16]. With recent
advances in genomics, and increased amounts of latent
detailed knowledge in the medical literature, computa-
tional approaches can now be developed to study the
importance of immune genes and their networks of
interactions linked to cancer progression.
Consequently, we have devised a strategy that assigns
a ranked immunological relevance score to all human
genes for the purpose of profiling the immune compo-
nent of tumor gene expression. Coupling text mining to
information theory, this approach charts immunological
relevance onto the human interactome. To apply this
strategy in a cancer specific manner, we analyzed mela-
nomas. We first identified immunological signatures
that were differentially regulated in the progression
from primary stages of skin cancer through to metas-
tases [17]. Survival data from a set of advanced stage
melanoma patients were also analyzed, to assess the link
between immunological relevance of genes in expression
profiles and clinical outcome [5,18].
Our computational approach to assign immunological
relevance to genes was benchmarked against manual
efforts that identify immune genes, and the strategy was
shown to substantiate the performance of existing
immunological grading systems. Furthermore, it identi-
fied the ranked immunological components of the
expression profile of a tumor with its associated net-
works of interactions. This informative grading of the
magnitude of the immune component from patient gene
expression profiles may serve as a computational diag-
nostic and prognostic guide to assess the aggressiveness
of a given tumor.
Results
An information theoretical approach to assign
immunological relevance to genes
A comprehensive list of 1921 immunology terms was
compiled by manual selection of the most relevant
terms from the standard biomedical vocabularies of
Medical Subject Headings (MeSH) in Medline and the
Gene Ontology (GO) controlled vocabulary (see Meth-
ods: “Defining the dictionary of terms for immune and
neoplasm relevance”). This broad set of terms was col-
lectively considered to be the immunological symbols of
communication stored in the over 20 million articles of
the biomedical literature (Additional file 1). Using estab-
lished text mining procedures [19] (see Methods:
“Extraction of human genes, immune and neoplasm
terms from Medline”), we used these terms and their
relationships to gene citations in Medline by capitalizing
on the universal feature of coded information, present in
all forms of communication. By this, it is implied that
immune relevant genes have a level of immune informa-
tion content quantified using this combined set of
immune terms in Medline, which is greater than that of
genes that play a lesser role in the immune system.
Information theory calculations were used to measure
the size of the immunological message stored for each
human gene with respect to these terms. The probabil-
ities in the information theory calculations were defined
through the frequency by which a given gene is cited
with a given immune term relative to the number of
times the immune term is cited in Medline among all
human genes with that term. This measure of immune
information content for a gene may be biased by the
higher frequency of certain genes being associated over-
all with the sources of the immune terms, i.e. the popu-
larity of a gene among all terms in the biomedical
vocabularies. This bias was corrected for using a method
in information theory known as the Kullback-Leibler
(KL) divergence (see Methods: “An immunological and
cancer relevance score for all human genes using infor-
mation theory and text mining”). The KL score for all
human genes was defined as the “immunological rele-
vance” for a gene and termed as such throughout this
study (Additional file 2). A similar strategy was also
applied to a manual selection of 562 cancer disease
terms to determine a genome-wide cancer relevance
score for every human gene.
Benchmarking of the immunological relevance score and
the extension of immune gene resources
In order to benchmark this immunological relevance for
genes, we compared the score against a set of validated
immune resources. We utilized gene sets from six
manually curated immune efforts (see Methods: “Collat-
ing manually curated immune relevant gene sets”)t h a t
contain independently annotated genes relevant for var-
ious aspects of immunity. There were a total of 4833
genes in this integrated set, which had a heterogeneous
distribution across the six resources, in that only 82
core immune genes were common to all databases.
Many genes in each resource were shared with merely
one of the other resources, and few genes were unique
to an individual resource (Figure 1). The benchmarking
of the immunological relevance score against this set of
manually curated immune resources is presented in
Figure 2A. The average immunological relevance score
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pared against each other and the genes not manually
curated by these resources. The Immunome [20] ranked
the highest among the six manually curated resources in
terms of immune information content, reflecting its
focus on collating genes enacting functions specific to
immune cells. When measuring the immunological rele-
vance of all genes assigned a name by the Human Gen-
ome Organization (HUGO) and not catalogued in any
of the immune resources, the average approaches zero.
The frequency distribution of immunological relevance
for all human genes assigned a name in HUGO shows a
sharp decline from high to low immunological relevance
(Figure 2B), revealing distinct categories of immune and
non-immune genes. Moreover, the top ranked genes in
the non-curated list represent novel candidates for entry
in immune resources (Additional file 3). To assess
further the benefit of assigning an automatic immunolo-
gical relevance score to genes, the integrated set of
manually curated genes was compared against two large
scale studies that have characterized the human inflam-
matory response: (1) the endotoxin response network
from gene expression profiling in human leukocytes
[21], and (2) the inflammation assembly, which consists
of genes detected in genetic variants in inflammatory
pathways [22]. The endotoxin response network and
inflammation assembly h a d6 6 %a n d1 3 %n o n - o v e r l a p -
ping genes with respect to the manually curated
resources. The non-correspondence of these six expert
resources with large-scale experimental efforts partly
indicates the specialized nature of some of these
resources and partly may indicate potential in further
management of immune knowledge from expert cura-
tors. It may also illustrate that there could still be more
genes to be implicated in human immunity that are as
yet uncharted.
The interactome landscape of immunological and cancer
relevance
An affirmed realization from the post genomic era is that
no gene functions in isolation, but rather is embedded in
a complex network of interacting molecules [23]. Our
strategy to profile the immune component of tumors
would therefore benefit from an analysis of how immu-
nological relevance relates to the position a gene occupies
in complex cellular networks (in this case an integration
of three human interactome databases, see Methods:
“Constructing a validated human interactome & network
analysis”). The creation of a validated and ranked score
of a gene’s immunological relevance allowed us to chart
this score in a landscape setting against cancer relevance
and the positional importance (centrality)o fag e n ei n
the interactome (Figure 3). Centrality is a class of net-
work measurements used to determine the relative
importance of a gene in cellular networks. We analyzed
five different centrality measures the principal of which
being connectivity (i.e. number of interactions per gene).
Genes from the six manually curated immune resources
on average had a higher connectivity relative the entire
interactome (data not shown). Interestingly, increasing
Figure 1 Heterogeneous distribution of genes in immune databases and an incomplete catalogue of immune knowledge.( A) Bar chart
depicting the shared gene distribution of the immune resources. 82 of the total integrated set of 4833 genes are common to all 6 manually
curate resources (orange colored bar). Few genes were unique to an individual database, ranging from a minimum of two for “Immunome” and
122 for the “Innate”.( B) An approximation using a Venn Euler diagram illustrates the heterogeneous overlap among the different databases. The
Innate database being the largest resource has the largest intersections. The septic shock resource has smaller overlaps with the others (with the
exception of Innate) highlighting its focus on collating genes related to the response to bacterial toxins during septic shock.
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correlation with connectivity or to any of the four other
network centrality measures (Additional file 4). The
immune and cancer genes harboring the highest connec-
tivity (network hubs) raise the average, and were
unevenly distributed across the heterogeneous interac-
tome landscape (Figure 3). This analysis allowed the
detection of scattered peak regions whose genes play dri-
ver roles in propagating signals with importance to
tumor-immune crosstalk. The classical coordinator of
Figure 2 Benchmarking of immunological relevance scores against manually curated immune resources. (A) T h em e a ni m m u n es c o r e
for each database is depicted in the bar chart. The core immune genes are those 82 genes that are common to all immune resources and have
a significantly larger amount of information content in comparison to each of the individual immune resources. (B) The frequency distribution of
all HUGO name assigned genes reveals a sharp decline in immune relevance across the genome.
Figure 3 The tumor-immunity interactome landscape. A three-dimensional surface plot representing the landscape of degree centrality
(connectivity) of the interactome in the context of immune and cancer relevance: All axes are on the log scale and values above one on the
log scale were considered high in terms of immune and cancer relevance. The consideration of one on the log scale as high in terms of
immune relevance is made on the basis of the average immune scores for the expert sources ranging from 1 bit and above (see Figure 2). The
color scale in the heatmap is representative of the connectivity of each gene in the human interactome. That which is apparent is the distinct
areas of scattered high and low connectivity for genes in the cancer-immune landscape. The underlying data for this plot is detailed in
Additional File 5.
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markers were among the highest ranked in this high peak
category, as displayed in the underlying interactome
landscape data in Additional file 5. We also observed a
high degree of correlation (0.75 Spearman’s coefficient)
between immunological and cancer information content
across the genome.
Immunological comparisons of normal tissues and
robustness of tissue specific immune interactions
As gene expression profiles of both normal and tumor
tissue represent the combined signal of all cell types pre-
sent in a sample: a global evaluation of the
immunological component of normal tissue profiles was
attempted, prior to the particular goal of quantifying
such for tumors. For this purpose, we calculated the pair-
wise fold change comparisons of the differentially
expressed genes among the 79 tissues profiles from the
SymAtlas project [24] and the average immunological
relevance score for those differentially expressed genes
(shown in heatmap Figure 4A). A gene was considered
differentially expressed if it had greater than a two-fold
d i f f e r e n c ei ne x p r e s s i o nb e t ween the two tissues under
comparison. The pairwise comparisons revealed hetero-
geneous differences in immunological components
among normal tissues (see heatmap in Figure 4A). The
Figure 4 Immunological components of normal tissue. (A) Heatmap of the immunological gene expression fold-change comparisons among
the 79 tissues from the SymAtlas [24]. This matrix displays the average immune score from those genes that contribute to greater than 2 times
fold change difference between each tissue’s pairwise comparisons. This combination of expression profiling and immunological grading detects
a heterogeneous difference in the immunological components between tissues in a global manner. Both the X and Y-axis are numerical index
of the 79 tissues (the mapping of this index to tissue name is listed in Additional File 8). With respect to the robustness of immune genes in the
interactome : (B) Tissue specific interactome networks for Wholeblood (eccentricity centrality = 0.67) and Heart (eccentricity centrality = 0.72).
The difference in the average eccentricity value is only marginally visible by eye as evidenced by a lower symmetry of the Heart network (the
same transparent circle drawn on top of the two networks displayed by means of the same algorithm using the software yEd).
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T-cells from the tissue SymAtlas [24] had the largest
immunological difference (see heatmap in Figure 4A, col-
umns No 48 and 50 for CD4 and CD8 respectively). The
procedure used to determine the differentially expressed
genes is detailed in the Methods section entitled: “Micro-
array gene expression analysis and a composite expres-
sion and immunological relevance score”.
In order to characterize the differences in the immuno-
logical component of these tissues from the perspective
of the interactome, we used tissue specific networks pre-
viously determined for the SymAtlas tissue profiles [25].
In addition to connectivity, we calculated four other net-
work centrality measures on each of these tissues net-
works (betweeness, eigenvector, closeness and
eccentricity). To test if any of these centrality measures is
a discernible property more specific to immune cells, we
implemented K-means clustering on all five of the cen-
trality measures across the tissues. Eccentricity was the
only measure that classified the tissues in a biological
meaningful manner (with K = 9 clusters), in that closely
related tissues clustered together (e.g. neurological or
immune related tissues, see cluster groups in Additional
file 6). Moreover the distribution of the gene eccentricity
centralities for each of the tissue interactome networks
showed that immune cells had the lowest average eccen-
t r i c i t yv a l u e s( s e eb r o w nl i n e s ,p e a kv a l u ea t0 . 6 3i n
Figure 5). Leukocytes clustered into three classes, with
CD4 and CD8 positive T-cells grouped with wholeblood,
lymphoblast precursors into their own separate class, and
the remainder of the blood cells profiled (including den-
dritic cells and NK cells) into a third class (Figure 5 and
cluster groups in Additional file 6). The interaction net-
work of a tissue (wholeblood) from the former immune
cluster was significantly different from a random network
(Wilcox rank, p-val of 0.01) and illustrated graphically in
a comparison of this network to that of a non-immune
tissue (heart) in Figure 4B. The difference in average
eccentricity values between these two tissues is margin-
ally visible in Figure 4B. As immune cells express more
immune relevant genes and their eccentricity measures
relate to shorter network distance, overall this tissue
group clustering suggests that immune genes have more
robust connections in the interactome.
Figure 5 Normalized frequency distribution of tissue specific eccentricity.T h ed i s t r i b u t i o n( i.e., normalized frequency) of the gene
eccentricity centralities for each of the tissue specific interactome networks (the same 79 human tissues profiled in Figure 4). Different network
groups can be classified on the basis of the maximal value of the eccentricity distribution. Some network groups have a differential maximal
value of distribution, and immune cells had the lowest values. The lower eccentricity values of immune cells reinforce the postulate that
immune genes have robust reach throughout the human interactome. Equal colors in the legend correspond to equal maximal values of the
normalized eccentricity.
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from expression profiles in melanoma patients
We next extended the principle of tissue expression pro-
filing of immunological signatures in normal tissue to
that of expression of normal skin, primary skin tumors
and metastatic melanoma [17]. From the pairwise com-
parison of genes with a greater than two-fold change in
expression across these different tissue states, we aver-
aged the immunological score for those genes differen-
tially expressed (> 2 times fold change) and examined
how this score differed across the various expression
profiles (see Figure 6). Using this average immunological
score, we detected clear differences in the stages of pro-
gression and related these comparisons to their immune
subnetworks from the interactome (see Figure 6). There
was a particularly high immunological difference
between normal melanocytes and both metastatic and
primary melanoma and between normal skin and both
metastatic and primary melanoma. The magnitude of
the immune component difference between metastatic
and normal melanocytes is depicted in Figure 6, along
with a related immunological subnetwork of interac-
tions. This network signature shows strong T-cell
activation as well as diverse tumor associated chemokine
and cytokine activity. There was, however, a much smal-
ler immunological difference between metastatic mela-
nomas and primary melanoma compared to that of
normal melanocytes (Figure 6). This suggested that the
framework could detect putative signatures of adaptive
immunity in mediating transitions at early stages of pro-
gression in these patients. The observation that the
highest ranked immune genes in these comparisons,
CD4 and CD8, were upregulated in primary melanoma
and metastasis compared to normal melanocytes signif-
ied early and enduring T-cell infiltration. In this com-
parison, immunological scoring also prioritized markers
of innate immune cells such as PECAM and CD14
among others, accompanied by cytokines of inflamma-
tory responses (I L 1 5 ,I L 7 ,I L 1 8 , IL1A, IL8). Interestingly,
there was also high ranking of an early Th2 tumor-pro-
moting environment demonstrated by presence of the
IL13RA2 gene and the Th1 inhibiting cytokine IL10.
The smaller amount of immunological information cap-
tured in the comparison of primary to metastatic mela-
noma (Figure 6) was attributable not to high scoring
leukocyte or inflammation markers, but by upregulation
Figure 6 Comparison of the immunological component of skin cancer and states of melanoma progression. A heatmap of the average
bits of immune information of the differentially expressed genes (> 2 times fold-change) among the pairwise comparisons of normal skin and
skin cancer states. The labels from the left to right columns refer to normal skin tissues: ("Normal”), normal melanocyte ("Melanocyte”) and then
various states of skin cancer: primary melanoma ("Primary”), squamous cell carcinoma ("Squamous”), basal cell carcinoma ("Basal”), in-situ
melanoma ("In Situ”) and metastatic melanoma ("Metastatic”). Distinct differences in the immunological component of the various skin cancer
and normal states are detected. We have focused here as an example, on the comparison between metastatic melanoma and normal human
melanocytes. A subnetwork module from the interactome landscape of those genes with high immunological relevance is displayed.
Upregulated genes are color-coded red and downregulated genes are color-coded green in this network. The size of a gene is proportional to
the immunological relevance of the gene. There is clearly increased T-cell activity such as the presence of increased expression of CD8, CD4 and
CD3 T-cell markers. This coincides with upregulation of key chemokine and cytokine interactions.
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downregulation of apoptosis inducing S100A8/9 cyto-
kines. Summarized gene lists of the top ranked immu-
nological transitions of normal skin, primary and
metastatic melanomas are presented in Table 1. In-situ
melanoma (MIS) compared to squamous cell carcinoma
(SCC) held the highest immunological difference among
all the state comparisons (Figure 6). Some of the top
ranked immune genes in that comparison included
upregulation in SCC relative to MIS of the chemokine
CXCL13 and downregulation of the innate immune
gene LTF
A composite gene expression and immunological rele-
vance score was used to grade each patient expression
profile and find clinical trends to immunological gene
signatures (see Methods: “Microarray gene expression
analysis and a composite expression and immunological
relevance score”). Although the Riker et al. study was not
accompanied by clinical outcome data, there was a trend
in two patients with giant primary melanomas (Breslow
thickness of 90 mm) and downregulation of highly rele-
vant immunological genes (p-val, 0.02) compared to 12
other patients with primary melanomas. Using this com-
posite grade, we examined the immunological differences
in the outcome, as well as in other clinical features of 57
patients that had reached metastatic melanoma at stage
IV [18] and 38 patients at stage III (Bogunovic et at,
2009). Notably, there was a significant association (p-val,
0) with the “high-immune” group of patients as anno-
tated by Jonsson et al (as identified by one term, chosen
a-priori). Similarly, the strategy detected downregulated
highly relevant immunological genes in the patient group
that fell into the “proliferative” group of patients (p-val,
0). An upregulated immunological trend was detected in
patients that had favorable survival (p-val, 0.1) and was
more significant (p-val, 0.02) in those patients categor-
ized with “brisk” immune phenotype (infiltration of CD3
positive lymphocytes). The patient group with NRAS
mutations (Q61L) had a correlation with downregulated
immunological signatures (p-val, 0.007), hence classifying
a group of patients with immune signaling interactions
acting downstream of this oncogenic mutation. Patients
with hypermethylation of the p16
INK4A promoter had
trends towards upregulation of genes with high
Table 1 Top ranked immunological transitions of melanoma progression
Gene comparison conditions Highest graded immune genes Significance to Melanoma progression
Upregulated (> 2fc) in both primary and
metastatic melanoma compared to normal
melanocyte (Immunological relevance score for
each gene (KL) > 11 bits).
CD4, IL10, CD8A, CD40, IL15, IL7, IL18,
TNFSF13B, PTPRC, IL13RA2, IL1A, PECAM1,
C5AR1, CD86, ISG20, IL18R1, CD14, ITGB2,
ADORA3, FCGR3A, CCL2, IL8, CCR5, FCGR3B
Signatures of T-cell infiltration, T-cell activation
and the inflammatory response. Inclusive of the
Th1 inhibiting cytokines
Downregulated (> 2fc) in both primary and
metastatic melanoma compared to normal
melanocyte (Immunological relevance score for
each gene (KL) > 0.5 bits).
MME, IL24, DPP4, CYGB, MSC, SLC7A8 Regulation of extracellular matrix (ECM)
remodeling, through proteolytic enzymes, and
amino acid transporters
Upregulated (> 2fc) in primary melanoma
compared to normal melanocyte. Not subject to
>2fc in metastasis (Immunological relevance
score for each gene (KL) > 2 bits).
IL5, TNF, IL1RN, DARC, HLA-DRB4, CFP, PTPN6,
CD1B, ELA2, IL17B, ATP8A2, SLPI, CD27, STAT4,
CDA, IL26, DEFB4, NFKBIA, HRH1, XCL1, DEFB1,
PDPN, CTSG, SDC1, GATA3, MSMB, CD24,
POU1F1, PRDM1, EBF1
Cytokine activity that is pro-survival and towards
ECM remodeling. Increased transcriptional
activity related to T-cell activation in the primary
tumor. Increased presence of MHC class II
markers.
Downregulated (> 2fc) in primary melanoma
compared to normal melanocyte. Not subject to
>2fc in metastasis (Immunological relevance
score for each gene (KL) > 1 bit).
BAX, TNFRSF10B, SV2A Down-regulation is indicative of p53
dysfunction and transduction of apoptosis
signals. Overall leading to pro-survival in the
primary tumor compared to normal cells
Upregulated (> 2fc) in metastatic melanoma
compared to normal melanocyte. Not subject to
>2fc in primary. (Immunological relevance score
for each gene (KL) > 1 bit).
CCRL2, HLA-DRB1, MDK, C4A, CD55, CD80,
FCGR1A, KLRC4, ICAM1, SPI1, HCST, PPBP,
FCGR2C, GPR160, CXCL16, FOS, SERPINA1
Mediators of inflammation, angiogenesis, cell
growth, and cell migration. Also present are
signals of humoral immunity in the form of T-
cell activation and B-cell development genes
Downregulated (> 2fc) in metastatic melanoma
compared to normal melanocyte. Not subject to
>2fc in primary. (Immunological relevance score
for each gene (KL) > 1 bit).
KIT, IRF4, MLANA, MMP1 Down regulation of cell adhesion, differentiation
factors and regulators of the innate and
adaptive immune systems. Possibly promoting
the metastatic phenotype
Upregulated (> 2fc) in metastatic melanoma
compared to primary (Immunological relevance
score for each gene (KL) < 1 bit).
MAGEA3, CSAG2, MAGEA2, GAGE1, MAGEA12,
GAGE3, FKBP10
Eliciting immune T cell activation in metastatic
tumors, as a consequence of being expressed
particularly in the metastatic stages, while
having very restricted expression in normal cells
Downregulated (> 2fc) in metastatic melanoma
compared to primary (Immunological relevance
score for each gene (KL) > 1 bit).
S100A9, S100A8, SLPI, DEFB4, DEFB1, MSMB,
CD24, DEFB103A, COL17A1
Altered matrix remodeling and migratory
behavior. Dynamic changes in the (ECM) in the
metastatic tumors. Inclusive in this is the down
regulation of important chemoattractants of
innate immune cells
Comparison of progressive melanoma states and their highest weighted immunological relevant genes.
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with immunological grading of these expression profiles
indicated that the assignment of an immunological rele-
vance to genes could classify patient groups with varied
immunological signatures. The same analysis was applied
to 38 patients from (Bogunovic et al, 2009), and it
revealed a significant correlation of upregulated immuno-
logical signatures in patients with prolonged survival (p-
val, 0.0086) and a significant correlation of downregu-
lated gene with patients that died (p-val, 0.0074). This
was also the case in Jonsson et al, where each patient had
a unique profile of clinical annotations and immunologi-
cal gene expression levels (Additional file 7). Interest-
ingly, the authors reported positive correlation with
tumor infiltrating leukocytes (TILs) in those patients
with favorable survival. A summary of these trends with
patient clinical annotations and the immunological pro-
files for each patient is listed in Additional file 7.
Discussion
The overlap between cancer and immunity has become
increasingly well established in recent years. Epidemiolo-
gically, 15-20% of cancer deaths are associated to inflam-
matory conditions [26]. Furthermore, inflammation is a
predisposition to cancer, and polymorphisms in cytokine
genes are associated to cancer severity [27,28]. Although
there is compelling evidence that supports this overlap,
an understanding of the molecular mechanisms of what
constitutes tumor-immune relationships is far from com-
prehensive [2,29]. This problem is complicated further by
the uniqueness of the microenvironment of each tumor,
and the complex interplay between cancer cell immune
factors and immune cells infiltrating the tumor.
Gene expression profiling has the potential to provide
an improved understanding of these complex relation-
ships and address these challenges. Current approaches
to assess the immune component of expression profiles
are dependent upon the application of limited pre-
defined sets of immune genes or terms. Prerequisite to
the success of manual approaches is the challenge of
defining the complete set of immune genes. We have
demonstrated that this challenge has not been met. The
crux in overcoming this challenge lies in what may be
considered to be an immune relevant gene. One option
to find immune genes with a role in cancer development
is the use of expertly annotated databases [20,30-32].
Our approach improves on the limitations of manual
approaches by applying a novel automated procedure
that quantifies the immunological relevance for all
human genes in bits of information. This score can be
directly applied to and provide a more informative and
quantitative assessment of the tumor immune compo-
nent from the gene expression profile. The novel use of
information bits to quantify the immunological
component may be even further generalized, and applied
to any phenotype or any other entity having been
assigned symbols of written communication.
Having access to a ranked immunological relevance
score for all genes provided an opportunity for analysis
of the resulting interactome landscape for tumor immu-
nity. This provided interesting insights into the relation-
ships with levels of immune and cancer information of a
gene in the interactome, in light of the new paradigm of
network biology [23,33]. These observations in particu-
lar add to the debate of the importance of central posi-
tions held by cancer [34] and immune [35] genes in the
cellular interactome network. Although there is on aver-
age higher connectivity for immune and cancer genes in
those studies, we illustrated variation about the average,
with certain peak genes raising the average connectivity
in the interactome landscape.
Tissue specific expression analysis of the immunologi-
cal relevance score demonstrated that there is a detect-
able difference among different tissues in the expression
of immune genes. Tissue specific network analysis
demonstrated that immune genes have distinguishably
robust connections within a cells interactome. These
observations may be explained by the diverse properties
of various tissues to interplay with the immune system
in maintaining tissue homeostasis. The strategy of apply-
ing a computationally derived immunological score to
capture the heterogeneity of the immunological compo-
nent of normal tissues adds reason to its application as
an immunological meta-analysis to cancer transcrip-
tomes. Indeed, quantifying the immunological compo-
nent of expression studies linked to clinical annotations
can lead to informative insights into the immune pro-
files of patient groups. The necessity and timeliness of
applying such a comprehensive computational strategy
to tumor expression profiles is highlighted by the
increasing reports of immune cell infiltrates in tumor
microenvironments as predictors of prognosis and survi-
val in various cancers [4,5,7,36-41].
A proposition for an immunological grading of a tumor
based on immune infiltrates has recently been made [42],
which would require the expertise of highly trained pathol-
ogists. Recent studies in malignant melanoma advocate
stratification based on molecular signatures from expres-
sion profiling [5,18]. The computational approach
described here serves in the automatic identification of
ranked immunological signatures and their network of
interactions, which leads to a strategy of grading the immu-
nological component of the gene expression of a tumor.
Melanoma was chosen to be the cancer type to
demonstrate this strategy, because of the prominent
immunological properties of normal skin [43,44] and
the strong tendency of melanoma to metastasize [45].
Among the genes harboring some of the highest
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ences in both primary and metastatic profiles compared
to normal skin, were the CD4 and CD8 genes. This indi-
cates that our strategy pinpoints possible recruitment of
the adaptive immune response at early points in the
progression of melanoma in these tumors, which is inter-
esting in the context of increasing evidence that adaptive
immunity influences the behavior of human tumors [36].
With respect to melanoma, this further coincides with
recent evidence in mice that the metastatic transition is
an early event, and that proliferation of disseminating
cells is mediated by the function of CD8
+ T-cells [46].
Concerning clinical analysis of metastatic melanoma
patients, this approach classified the patient group that
had immune signatures of upregulated high immunologi-
cally relevant genes, and the proliferative-tumor group
with down downregulation of high immunologically rele-
vant genes. It was apparent from the clinical analysis that
patients had unique combinations of clinical annotations
with both up and downregulated genes with high immu-
nological scores. The distinctive immunological profiles
for each patient may reflect the uniqueness of the
immune component of each microenvironment and the
contradictory role immune genes play in regulating can-
cer development [47].
This strategy does not grade the directionality of these
paradoxical roles in the tumor immune response.
Rather, it identifies and grades the magnitude of the
immune component of the expression profiles. We pro-
pose, however, that improving this strategy to do so will
precipitate the characterization of detailed mechanisms
underlying tumor-immune surveillance, tolerance and
escape and facilitate identification of powerful prognos-
tic factors.
Conclusions
We have assigned a ranked immunological relevance
score to all human genes applying a novel computa-
tional approach that utilizes information theory applied
to the medical literature. This score was used to chart
immunological relevance against the landscape of pro-
tein interaction networks. We propose that this
approach can be applied to elucidate the phenotypical
component of any complex disease. In this study we
focus on tumor immunity and melanoma to demon-
strate the ability of this strategy to identify and grade
the magnitude of the immune component of patient
expression profiles. The capability to analyze tumor
transcriptional profiles on a genome-wide scale offers a
means to investigate the immunological mechanisms of
the complex tumor immune relationships. In so doing,
such an approach can classify melanoma patient groups
into varied immune profiles that correlate with survival
and other clinical phenotypes.
Methods
Defining the dictionary of terms for immune and
neoplasm relevance
By doing manual searches in the Gene Ontology (GO)
[48] and the Medical Subject Headings (MeSH) (http://
www.nlm.nih.gov/mesh/) resources and documenting
those terms deemed relevant for the context, we com-
piled a list of 1921 immune and 562 neoplasm context
terms. This resulted in a comprehensive term list from
structured vocabularies that define the contexts in our
analysis. The manual searches were implemented using
domain knowledge of immunity and cancer. Strict scru-
tiny of relevance to the context was applied before
acceptance of a term into the context term list. The
manual searches in MesH and GO produced a candidate
list of terms. Each candidate term was read and then
categorized as being relevant or not relevant for immu-
nity or cancer based on the expert knowledge of an
immunologist or cancer researcher, respectively. As the
purpose of this study was toq u a n t i f yt h es i z eo ft h e
immune component of tumor samples, a broad scope of
immune terms was accepted, each term has an associa-
tion of an immune function, process, cellular anatomy
or immune condition according to the scrutiny of the
immunologist. The complete list of chosen immune and
neoplasm terms is presented in Additional file 1.
Extraction of human genes, immune and neoplasm terms
from Medline
One of the important elements in the approach is to
identify literature co-citations of human genes and their
associated GO and MeSH terms by using an established
method in text mining [19]. Here is a brief summary of
this method with more detail in the referenced article.
All official symbols, names and alias symbols for human
genes compiled from the Human Genome Organization
(HUGO) (http://www.genenames.org/), OMIM (http://
www.ncbi.nlm.nih.gov/omim/), and EntrezGene (http://
www.ncbi.nlm.nih.gov/gene), were automatically
extracted from all Medline article titles and abstracts.
The genes are indexed to PubMed IDs after a natural
language processing (NLP) step of the Medline abstracts
that involves procedures in part of speech tagging (POS)
and noun chunking, the purpose of which is to remove
false positives of biological term mentions. Some other
steps in obtaining the gene citation data of higher qual-
ity is to remove abbreviation type false positives, which
occur frequently because gene symbols often coincide
with other abbreviations having no connection or rele-
vancy with the gene symbol. Such data quality steps
yield a greater number unambiguous gene symbol cita-
t i o n si nt e x tw i t ha ni m p r o v e dp r e c i s i o n .I nas i m i l a r
manner to the extractions of gene from Medline text
GO terms are extracted using NLP techniques of POS
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tifiers and indexed against noun chunks in Medline sen-
tences. MeSH terms are indexed to Medline abstracts by
using the National Library of Medicine’s (NLM) annota-
tions of MeSH terms to articles.
An immunological and cancer relevance score for all
human genes using information theory and text mining
The principle of Shannon’s entropy was first tested as a
sensible measure of information content applied to gene
associations derived from text mining. This was further
refined using the Kullback-Leibler (KL) score, thus cor-
recting for bias introduced by the popularity of the gene
to be co-cited in all of Medline which we found to
inherent in the Shannon entropy calculations.
In these information theory aproach we interpreted
gene co-citation events in medical articles with terms
from a lexicon of expertly chosen annotations from a
context as an information coding system for the context
(the context of immunity and cancer in this study). The
frequency of co-citation events of a manually annotated
context term i extracted from Medline abstracts using
text mining and co-cited with a human gene x is treated
as a message. This message is detected within each ele-
ment of an alphabet of symbols of size N,w h e r eN is
the total number of annotated terms in the lexicon of
that context. Immune and cancer experts manually
chose the elements of the alphabet of symbols N from
the structured biological vocabularies of GO and MeSH.
Thus we view the literature association between a gene
and a context term as the observance of a symbol
describing an element of that contextual message and
the probability of that event occurring is:
p(x)=
gi
iTg
gi is the number of co-citations for a gene with a con-
text term i in Medline and iTg is the total number of
times the context term i is cited with all human genes in
all of Medline (the total gene co-citation space of the
context term). Hence, the continuously expanding 20
million articles of Medline is the source emitting these
symbols with probabilities (p1, p2, . . ., pN)a n dt h e s ea r e
the symbols of communication that define an immunolo-
gical (or other contextual) score for all human genes. We
assume that the symbols are emitted independently for
each gene. In this assumption the probability that a gene
is associated to, for example, the immune term “T-cell
differentiation” in Medline is independent of its associa-
tion to the immune term “Macrophage” and their prob-
abilities are computed independently. These probabilities
of events (p1, p2, . . ., pN) give discrete values that can be
used to detect the size of a message and thus the
contextual information content for each gene as defined
by Shannon’s entropy [49]
Hc =
N 
i
p(x)log2p(x)
Although the Shannon entropy provided the accurate
size of the information content for each gene, it did not
account for bias introduced by the popularity of the
gene Medline. We therefore refined the information the-
ory approach to correct for this bias. This bias was
defined as the popularity of the gene to be co-cited in
all of Medline, i.e. its probability of co-citation among
all GO and MeSH terms in the gene co-citation space
of Medline. We quantified this bias and corrected for it
using the Kullback-Leibler (KL or “relative entropy”) cal-
culation to create a more accurate measure of informa-
tion content that can be used as the immunological and
cancer score for each gene. The KL was used to deter-
mine the divergence of the observed probability p(x),
described above, from an assumed incorrect distribution,
which we take as the popularity of the gene in the total
Medline gene co-citation space q(x):
q(x)=
gT
GST
Where gT is the number of co-citations for a gene
with all GO and MeSH terms in Medline and GST is the
total number of co-citation events for all GO and MeSH
terms with all human genes in all of Medline (the total
gene co-citation space of GO and MeSH, the source of
the immune and cancer context terms chosen by
domain experts). This measures the expected amount of
information required to code a message from a context
term for a gene p(x) when using a code based on the
assumed incorrect probability q(x) rather than using a
code based on p(x) and is defined by Kulback-Leibler
KL as:
KL =
N 
i
p(x)log2
p(x)
q(x)
As this relative entropy score (KL) corrects for the
bias q(x) for each gene, it was used as to calculate the
“immunological and cancer relevance” score throughout
this study.
Collating manually curated immune relevant gene sets
The immunology gene sets were compiled from the fol-
lowing manually curated sources: (1) Immport (https://
www.immport.org), (2) Immunome [20], (3) Iris [31], (4)
Mapk-Nfkb (ref), (5) Septic Shock (http://www.septic-
shock.org) and (6) InnateDB [30]. The HUGO (http://
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unique identifier for human genes and is ideal for the
integration of text mining derived knowledge. It was
used in this study to integrate and determine the over-
lapping descriptive statistics for each of the six databases
and visualized in Venn diagrams in the VennMaster
software [50] to approximate their intersections by
incorporating the gene set size information. Similarly
genes from two efforts to catalogue the inflammatory
response [21,22] were integrated using their HUGO
gene symbols and compared to the unified immune
gene set from the above six different sources mentioned
above.
Constructing a validated human interactome & network
analysis
We constructed a human gene network by integrating
binary human interactions from IntAct [51], BioGRID
[51] and HPRD [52]. Each of these datasets of binary
interacting protein pairs was downloaded from their
source and the unique ids of the interactors were cross-
referenced to their NCBI gene IDs and official Gene
Symbols. This resulted in a unified set of binary NCBI
gene ID interactor pairs, with their corresponding offi-
cial gene symbols. The interaction data was limited to
these sources as they consist of validated protein-protein
interactions with experimental evidence curated from
critical reading of the scientific literature by expert
biologists.
This integrated data set is represented as an undir-
ected, unweighted network, where G = (V,E) comprising
of a set of nodes V and edges E. Each node represents a
human gene and each edge represents a pair of genes
(u,v) as a representation of a binary interaction in the
human interactome. If there exists a physical binary
interaction between u and v, in at least one of the pro-
tein products of each gene, an edge is connected. The
tissue specific interactomes were derived from the
entries in the three protein interaction databases men-
tioned above and the tissue expression annotations from
in a recent study integrating tissue specific interactions
from 79 human tissues [25].
Network centrality analysis was carried out on the
networks by means of calculating five measures of cen-
trality for each gene in the interactome (Connectivity,
betweeness, eccentricity, closeness and eigenvector). A
descriptions of equations implemented for these mea-
sures and full details of their context to protein net-
works in cancer are summarized here [53]
Microarray gene expression analysis and a composite
expression and immunological relevance score
Tissue specific gene expression data from the Symatlas
project [24] was analyzed to detect pairwise differential
expression across the 79 specific tissues [25] (Additional
file 8). We considered a gene differentially expressed
between any pair of tissues and therefore viable for
further analysis if there was greater than a two times
fold-change in expression. The average immunological
score was then determined for these differentially
expressed genes across all tissue pairs. A similar
approach was used for profiles in the progressive states
of skin cancer. For the gene expression profile linked to
patient survival probes [18] strict criteria were applied to
reduce false positive signals in that only those probes
with detection p-value < 0.01 in more than 50 out of the
total 57 patients were used. The software used to calcu-
late the detection p-values (Illumina BeadStudio) uses a
nonparametric method for the computation of detection
p-values. In this method the z-values of the probe signals
are ranked relative to the z-values of the negative control
signals. These were quantile normalized [54], and log2
transformed. Each probe signal intensity measurement
(S) was given a fold change relative to that probes mean
signal intensity (MSI) across all patients (P) and utilized
to create a weighed composite signal intensity and immu-
nological score for each gene (Wg):
P 
1
log2(
S
MSI
).KL
The weighted expression and immune score for each
gene was then summated across all genes (M) for each
patient to generated a weighted immune score for each
patient (Wp):
M 
1
Wg
The patient scores where compared to the clinical
annotations to find correlations between the weighted
immunological score (Wp) and the clinical phenotypes.
Monte Carlo simulations with 10,000 draws were used
to create a null distribution for each comparison. For
numerical phenotypes Pearson’s correlation were used.
Additional material
Additional file 1: Tables of manually curated immune and neoplasia
terms. These are the terms used to define the dictionary of terms for
immune and neoplasm context. Manually selected from GO and MeSH
using domain knowledge.
Additional file 2: Genome-wide ranked Immunological and
neoplasia relevance score for genes. Table depicting the
immunological and cancer relevance score for all human genes
quantified in bits using information theory calculation with Kullback-
Leibler adjustments
Additional file 3: Immunological relevance of non-curated genes.
Ranked immunological relevance of genes not populated in the
manually curated immune gene resources
Clancy et al. BMC Medical Genomics 2011, 4:28
http://www.biomedcentral.com/1755-8794/4/28
Page 12 of 14Additional file 4: Relationship of both immunological and cancer
relevance to network centrality. Tables reporting the Pearson
correlation coefficients of immunological and cancer relevance to the
principle network centrality measures of the human interactome.
Additional file 5: Tumor immunity interactome landscape. The
underlying data behind Figure 3, quantifying in bits of information the
immunological and cancer relevance charted against connectivity in the
interacome
Additional file 6: Table of the k-means classification by means of
the eccentricity centrality measure, showing biologically
meaningful classes of tissues. K-means classification of tissue groups
shown in Figure 5 (parameter K = 9). Determined by means of the
eccentricity centrality measure for each of the tissue specific
interactomes from the SymAtlas [24].
Additional file 7: Bogunovic et al, 2009 distinct patient profiles and
relationship to clinical phenotypes. Composite expression and
immunological relevance score for all genes in each patient in this study.
Demonstrated here as an example to offer an overview of the diversity
and uniqueness of the immunological profile, detected by this approach
in each individual patient samples.
Additional file 8: Normal tissue index. Index for the 79 normal tissues
from the SymAtlas [24] depicted in the heatmap of immunological
comparisons in Figure 4A
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